Plakoglobin interacts with the transcription factor p53 and regulates the expression of 14-3-3σ

Journal of Cell Science

Volumn 126, Issue 14, 2013, Pages 3031-3042

  Aktary, Zackie ^a   Kulak, Stephen ^a   Mackey, John ^a   Jahroudi, Nadia ^a   Pasdar, Manijeh ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

14 3 3 ; Gene expression; p53; Plakoglobin; SCC9; Tumor suppressor

Indexed keywords

PLAKOGLOBIN; PROTEIN P53; STRATIFIN;

ARTICLE; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REGULATORY MECHANISM;

14-3-3Σ; GENE EXPRESSION; P53; PLAKOGLOBIN; SCC9; TUMOR SUPPRESSOR;

14-3-3 PROTEINS; CARCINOGENESIS; FEMALE; GAMMA CATENIN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TRANSGENES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84880658456     PISSN: 00219533     EISSN: 14779137     Source Type: Journal    
DOI: 10.1242/jcs.120642     Document Type: Article

References (102)

1. Aktary, Z. and Pasdar, M. (2012). Plakoglobin: role in tumorigenesis and metastasis. Int. J. Cell Biol. 2012, 189521.
2. Aktary, Z., Chapman, K., Lam, L., Lo, A., Ji, C., Graham, K., Cook, L., Li, L., Mackey, J. R. and Pasdar, M. (2010). Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1. Oncogene 29, 2118-2129.
3. Aprelikova, O., Pace, A. J., Fang, B., Koller, B. H. and Liu, E. T. (2001). BRCA1 is a selective co-activator of 14-3-3 σ gene transcription in mouse embryonic stem cells. J. Biol. Chem. 276, 25647-25650.
4. Bailey, C. K., Mittal, M. K., Misra, S. and Chaudhuri, G. (2012). High motility of triple-negative breast cancer cells is due to repression of plakoglobin gene by metastasis modulator protein SLUG. J. Biol. Chem. 287, 19472-19486.
5. Benzinger, A., Muster, N., Koch, H. B., Yates, J. R., 3rd and Hermeking, H. (2005). Targeted proteomic analysis of 14-3-3 σ, a p53 effector commonly silenced in cancer. Mol. Cell. Proteomics 4, 785-795.
6. Bhatia, K., Siraj, A. K., Hussain, A., Bu, R. and Gutiérrez, M. I. (2003). The tumor suppressor gene 14-3-3 s is commonly methylated in normal and malignant lymphoid cells. Cancer Epidemiol. Biomarkers Prev. 12, 165-169.
7. Boehme, K. A. and Blattner, C. (2009). Regulation of p53-insights into a complex process. Crit. Rev. Biochem. Mol. Biol. 44, 367-392.
8. Brosh, R. and Rotter, V. (2009). When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9, 701-713.
9. Cai, B. H., Chen, J. Y., Lu, M. H., Chang, L. T., Lin, H. C., Chang, Y. M. and Chao, C. F. (2009). Functional four-base A/T gap core sequence CATTAG of P53 response elements specifically bound tetrameric P53 differently than two-base A/T gap core sequence CATG bound both dimeric and tetrameric P53. Nucleic Acids Res. 37, 1984-1990.
10. Chandrachud, U. and Gal, S. (2009). Three assays show differences in binding of wildtype and mutant p53 to unique gene sequences. Technol. Cancer Res. Treat. 8, 445-453.
11. Charpentier, E., Lavker, R. M., Acquista, E. and Cowin, P. (2000). Plakoglobin suppresses epithelial proliferation and hair growth in vivo. J. Cell Biol. 149, 503-520.
12. Chidgey, M. and Dawson, C. (2007). Desmosomes: a role in cancer? Br. J. Cancer 96, 1783-1787.
13. Cicalese, A., Bonizzi, G., Pasi, C. E., Faretta, M., Ronzoni, S., Giulini, B., Brisken, C., Minucci, S., Di Fiore, P. P. and Pelicci, P. G. (2009). The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138, 1083-1095.
14. Collavin, L., Lunardi, A. and Del Sal, G. (2010). p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 17, 901-911.
15. Damalas, A., Ben-Ze'ev, A., Simcha, I., Shtutman, M., Leal, J. F. M., Zhurinsky, J., Geiger, B. and Oren, M. (1999). Excess b-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18, 3054-3063.
16. Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A. and Oren, M. (2001). Deregulated b-catenin induces a p53-and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 20, 4912-4922.
17. Danilov, A. V., Neupane, D., Nagaraja, A. S., Feofanova, E. V., Humphries, L. A., DiRenzo, J. and Korc, M. (2011). DeltaNp63alpha-mediated induction of epidermal growth factor receptor promotes pancreatic cancer cell growth and chemoresistance. PLoS ONE 6, e26815.
18. de Stanchina, E., Querido, E., Narita, M., Davuluri, R. V., Pandolfi, P. P., Ferbeyre, G. and Lowe, S. W. (2004). PML is a direct p53 target that modulates p53 effector functions. Mol. Cell 13, 523-535.
19. Dusek, R. L., Godsel, L. M., Chen, F., Strohecker, A. M., Getsios, S., Harmon, R., Müller, E. J., Caldelari, R., Cryns, V. L. and Green, K. J. (2007). Plakoglobin deficiency protects keratinocytes from apoptosis. J. Invest. Dermatol. 127, 792-801.
20. El-Bahrawy, M., Poulsom, R., Rowan, A. J., Tomlinson, I. T. and Alison, M. R. (2004). Characterization of the E-cadherin/catenin complex in colorectal carcinoma cell lines. Int. J. Exp. Pathol. 85, 65-74.
21. Franzen, C. A., Todorović, V., Desai, B. V., Mirzoeva, S., Yang, X. J., Green, K. J. and Pelling, J. C. (2012). The desmosomal armadillo protein plakoglobin regulates prostate cancer cell adhesion and motility through vitronectin-dependent Src signaling. PLoS ONE 7, e42132.
22. Garrod, D. and Chidgey, M. (2008). Desmosome structure, composition and function. Biochim. Biophys. Acta 1778, 572-587.
23. Goh, A. M., Coffill, C. R. and Lane, D. P. (2011). The role of mutant p53 in human cancer. J. Pathol. 223, 116-126.
24. Halbleib, J. M. and Nelson, W. J. (2006). Cadherins in development: cell adhesion, sorting, and tissue morphogenesis. Genes Dev. 20, 3199-3214.
25. Harris, S. L. and Levine, A. J. (2005). The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908.
26. Hermeking, H., Lengauer, C., Polyak, K., He, T. C., Zhang, L., Thiagalingam, S., Kinzler, K. W. and Vogelstein, B. (1997). 14-3-3 s is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1, 3-11.
27. Holen, I., Whitworth, J., Nutter, F., Evans, A., Brown, H. K., Lefley, D. V., Barbaric, I., Jones, M. and Ottewell, P. D. (2012). Loss of plakoglobin promotes decreased cell-cell contact, increased invasion, and breast cancer cell dissemination in vivo. Breast Cancer Res. 14, R86.
28. Huang, H. and He, X. (2008). Wnt/beta-catenin signaling: new (and old) players and new insights. Curr. Opin. Cell Biol. 20, 119-125.
29. Jeanes, A., Gottardi, C. J. and Yap, A. S. (2008). Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27, 6920-6929.
30. Jung, M., Notario, V. and Dritschilo, A. (1992). Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res. 52, 6390-6393.
31. Junttila, M. R. and Evan, G. I. (2009). p53-a Jack of all trades but master of none. Nat. Rev. Cancer 9, 821-829.
32. Kanazawa, Y., Ueda, Y., Shimasaki, M., Katsuda, S., Yamamoto, N., Tomita, K. and Tsuchiya, H. (2008). Down-regulation of plakoglobin in soft tissue sarcoma is associated with a higher risk of pulmonary metastasis. Anticancer Res. 28 2A, 655-664.
33. Kern, S. E., Pietenpol, J. A., Thiagalingam, S., Seymour, A., Kinzler, K. W. and Vogelstein, B. (1992). Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256, 827-830.
34. Kim, D., Yang, J. Y. and Shin, C. S. (2009). Overexpression of a-catenin increases osteoblastic differentiation in mouse mesenchymal C3H10T1/2 cells. Biochem. Biophys. Res. Commun. 382, 745-750.
35. Klymkowsky, M. W., Williams, B. O., Barish, G. D., Varmus, H. E. and Vourgourakis, Y. E. (1999). Membrane-anchored plakoglobins have multiple mechanisms of action in Wnt signaling. Mol. Biol. Cell 10, 3151-3169.
36. Kolligs, F. T., Kolligs, B., Hajra, K. M., Hu, G., Tani, M., Cho, K. R. and Fearon, E. R. (2000). gamma-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of beta-catenin. Genes Dev. 14, 1319-1331.
37. Kwok, T. T., Mok, C. H. and Menton-Brennan, L. (1994). Up-regulation of a mutant form of p53 by doxorubicin in human squamous carcinoma cells. Cancer Res. 54, 2834-2836.
38. Lai, Y.-H., Cheng, J., Cheng, D., Feasel, M. E., Beste, K. D., Peng, J., Nusrat, A. and Moreno, C. S. (2011). SOX4 interacts with plakoglobin in a Wnt3a-dependent manner in prostate cancer cells. BMC Cell Biol. 12, 50.
39. Lam, L., Hu, X., Aktary, Z., Andrews, D. W. and Pasdar, M. (2009). Tamoxifen and ICI 182,780 increase Bcl-2 levels and inhibit growth of breast carcinoma cells by modulating PI3K/AKT, ERK and IGF-1R pathways independent of ERalpha. Breast Cancer Res. Treat. 118, 605-621.
40. Lam, L., Aktary, Z., Bishay, M., Werkman, C., Kuo, C. Y., Heacock, M., Srivastava, N., Mackey, J. R. and Pasdar, M. (2012). Regulation of subcellular distribution and oncogenic potential of nucleophosmin by plakoglobin. Oncogenesis 1, e4.
41. Lamy, V., Bousserouel, S., Gossé, F., Minker, C., Lobstein, A. and Raul, F. (2010). p53 Activates Either Survival or Apoptotic Signaling Responses in Lupulone-Treated Human Colon Adenocarcinoma Cells and Derived Metastatic Cells. Transl. Oncol. 3, 286-292.
42. Lee, M. H. and Lozano, G. (2006). Regulation of the p53-MDM2 pathway by 14-3-3 s and other proteins. Semin. Cancer Biol. 16, 225-234.
43. Li, Y., Mao, Y., Rosal, R. V., Dinnen, R. D., Williams, A. C., Brandt-Rauf, P. W. and Fine, R. L. (2005). Selective induction of apoptosis through the FADD/caspase-8 pathway by a p53 c-terminal peptide in human pre-malignant and malignant cells. Int. J. Cancer 115, 55-64.
44. Li, L., Chapman, K., Hu, X., Wong, A. and Pasdar, M. (2007). Modulation of the oncogenic potential of beta-catenin by the subcellular distribution of plakoglobin. Mol. Carcinog. 46, 824-838.
45. Li, F. Q., Mofunanya, A., Harris, K. and Takemaru, K.-I. (2008). Chibby cooperates with 14-3-3 to regulate b-catenin subcellular distribution and signaling activity. J. Cell Biol. 181, 1141-1154
46. Lin, D.-L. and Chang, C. (1996). p53 is a mediator for radiation-repressed human TR2 orphan receptor expression in MCF-7 cells, a new pathway from tumor suppressor to member of the steroid receptor superfamily. J. Biol. Chem. 271, 14649-14652.
47. Lindenboim, L., Borner, C. and Stein, R. (2011). Nuclear proteins acting on mitochondria. Biochim. Biophys. Acta 1813, 584-596.
48. Lodygin, D. and Hermeking, H. (2006). Epigenetic silencing of 14-3-3sigma in cancer. Semin. Cancer Biol. 16, 214-224.
49. MacDonald, B. T., Tamai, K. and He, X. (2009). Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9-26.
50. Makrilia, N., Kollias, A., Manolopoulos, L. and Syrigos, K. (2009). Cell adhesion molecules: role and clinical significance in cancer. Cancer Invest. 27, 1023-1037.
51. Meek, D. W. (2009). Tumour suppression by p53: a role for the DNA damage response? Nat. Rev. Cancer 9, 714-723.
52. Menendez, D., Inga, A. and Resnick, M. A. (2009). The expanding universe of p53 targets. Nat. Rev. Cancer 9, 724-737.
53. Mihara, M., Erster, S., Zaika, A., Petrenko, O., Chittenden, T., Pancoska, P. and Moll, U. M. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol. Cell 11, 577-590.
54. Morrison, D. K. (2009). The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development. Trends Cell Biol. 19, 16-23.
55. Muller, P. A. and Vousden, K. H. (2013). p53 mutations in cancer. Nat. Cell Biol. 15, 2-8.
56. Muller, P. A. J., Trinidad, A. G., Timpson, P., Morton, J. P., Zanivan, S., van den Berge, P. V. E., Nixon, C., Karim, S. A., Caswell, P. T., Noll, J. E. et al. (2013). Mutant p53 enhances MET trafficking and signaling to drive cell scattering and invasion. Oncogene 32, 1252-1265.
57. Nakanishi, K., Kumaki, F., Hiroi, S., Mukai, M., Ikeda, E. and Kawai, T. (2006). Mre11 expression in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Arch. Pathol. Lab. Med. 130, 1330-1334.
58. Närkiö-Mäkelä, M., Pukkila, M., Lagerstedt, E., Virtaniemi, J., Pirinen, R., Johansson, R., Kosunen, A., Lappalainen, K., Hämäläinen, K. and Kosma, V. M. (2009). Reduced gamma-catenin expression and poor survival in oral squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 135, 1035-1040.
59. Neilsen, P. M., Cheney, K. M., Li, C. W., Chen, J. D., Cawrse, J. E., Schulz, R. B., Powell, J. A., Kumar, R. and Callen, D. F. (2008). Identification of ANKRD11 as a p53 coactivator. J. Cell Sci. 121, 3541-3552.
60. Noll, J. E., Jeffery, J., Al-Ejeh, F., Kumar, R., Khanna, K. K., Callen, D. F. and Neilsen, P. M. (2012). Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. Oncogene 31, 2836-2848.
61. Nozoe, T., Oyama, T., Uramoto, H., Takenoyama, M., Hanagiri, T., Sugio, K. and Yasumoto, K. (2009). Reduced expression of catenin subtypes is a potential indicator of unfavorable prognosis in esophageal squamous cell carcinoma. Mol. Med. Rep. 2,353-357.
62. O'Farrell, T. J., Ghosh, P., Dobashi, N., Sasaki, C. Y. and Longo, D. L. (2004). Comparison of the effect of mutant and wild-type p53 on global gene expression. Cancer Res. 64, 8199-8207.
63. Obsilová, V., Silhan, J., Boura, E., Teisinger, J. and Obsil, T. (2008). 14-3-3 proteins: a family of versatile molecular regulators. Physiol. Res. 57 Suppl. 3, S11-S21.
64. Oren, M. and Rotter, V. (2010). Mutant p53 gain-of-function in cancer. Cold Spring Harb. Perspect. Biol. 2, a001107.
65. Pan, Y. and Haines, D. S. (2000). Identification of a tumor-derived p53 mutant with novel transactivating selectivity. Oncogene 19, 3095-3100.
66. Pantel, K., Passlick, B., Vogt, J., Stosiek, P., Angstwurm, M., Seen-Hibler, R., Häussinger, K., Thetter, O., Izbicki, J. R. and Riethmü ller, G. (1998). Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J. Clin. Oncol. 16, 1407-1413.
67. Parker, H. R., Li, Z., Sheinin, H., Lauzon, G. J. and Pasdar, M. (1998). Plakoglobin induces desmosome formation and epidermoid phenotype in N-cadherin-expressing squamous carcinoma cells deficient in plakoglobin and E-cadherin. Cell Motil. Cytoskeleton 40, 87-100.
68. Pasdar, M., Li, Z. and Chlumecky, V. (1995). Plakoglobin: kinetics of synthesis, phosphorylation, stability, and interactions with desmoglein and E-cadherin. Cell Motil. Cytoskeleton 32, 258-272.
69. Peifer, M., McCrea, P. D., Green, K. J., Wieschaus, E. and Gumbiner, B. M. (1992). The vertebrate adhesive junction proteins beta-catenin and plakoglobin and the Drosophila segment polarity gene armadillo form a multigene family with similar properties. J. Cell Biol. 118, 681-691.
70. Peng, Y. and Jahroudi, N. (2003). The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases. J. Biol. Chem. 278, 8385-8394.
71. Perez, R. E., Knights, C. D., Sahu, G., Catania, J., Kolukula, V. K., Stoler, D., Graessmann, A., Ogryzko, V., Pishvaian, M., Albanese, C. et al. (2010). Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway. J. Cell. Physiol. 225, 394-405.
72. Prasad, G. L., Valverius, E. M., McDuffie, E. and Cooper, H. L. (1992). Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells. Cell Growth Differ. 3, 507-513.
73. Pulukuri, S. M. and Rao, J. S. (2006). CpG island promoter methylation and silencing of 14-3-3s gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene 25, 4559-4572.
74. Rahman-Roblick, R., Roblick, U. J., Hellman, U., Conrotto, P., Liu, T., Becker, S., Hirschberg, D., Jörnvall, H., Auer, G. and Wiman, K. G. (2007). p53 targets identified by protein expression profiling. Proc. Natl. Acad. Sci. USA 104, 5401-5406.
75. Rasti, M., Arabsolghar, R., Khatooni, Z. and Mostafavi-Pour, Z. (2012). p53 Binds to estrogen receptor 1 promoter in human breast cancer cells. Pathol. Oncol. Res. 18, 169-175.
76. Rieger-Christ, K. M., Ng, L., Hanley, R. S., Durrani, O., Ma, H., Yee, A. S., Libertino, J. A. and Summerhayes, I. C. (2005). Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br. J. Cancer 92, 2153-2159.
77. Salomon, D., Sacco, P. A., Roy, S. G., Simcha, I., Johnson, K. R., Wheelock, M. J. and Ben-Ze'ev, A. (1997). Regulation of b-catenin levels and localization by overexpression of plakoglobin and inhibition of the ubiquitin-proteasome system. J. Cell Biol. 139, 1325-1335.
78. Sang, M., Li, Y., Ozaki, T., Ono, S., Ando, K., Yamamoto, H., Koda, T., Geng, C. and Nakagawara, A. (2006). p73-dependent induction of 14-3-3s increases the chemo-sensitivity of drug-resistant human breast cancers. Biochem. Biophys. Res. Commun. 347, 327-333.
79. Scharer, C. D., McCabe, C. D., Ali-Seyed, M., Berger, M. F., Bulyk, M. L. and Moreno, C. S. (2009). Genome-wide promoter analysis of the SOX4 transcriptional network in prostate cancer cells. Cancer Res. 69, 709-717.
80. Schreiber, E., Matthias, P., Mü ller, M. M. and Schaffner, W. (1989). Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res. 17, 6419.
81. Setzer, S. V., Calkins, C. C., Garner, J., Summers, S., Green, K. J. and Kowalczyk, A. P. (2004). Comparative analysis of armadillo family proteins in the regulation of a431 epithelial cell junction assembly, adhesion and migration. J. Invest. Dermatol. 123, 426-433.
82. Shtutman, M., Zhurinsky, J., Oren, M., Levina, E. and Ben-Ze'ev, A. (2002). PML is a target gene of b-catenin and plakoglobin, and coactivates b-catenin-mediated transcription. Cancer Res. 62, 5947-5954.
83. Simcha, I., Geiger, B., Yehuda-Levenberg, S., Salomon, D. and Ben-Ze'ev, A. (1996). Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J. Cell Biol. 133, 199-209.
84. Simcha, I., Shtutman, M., Salomon, D., Zhurinsky, J., Sadot, E., Geiger, B. and Ben-Ze'ev, A. (1998). Differential nuclear translocation and transactivation potential of b-catenin and plakoglobin. J. Cell Biol. 141, 1433-1448.
85. Sinner, D., Kordich, J. J., Spence, J. R., Opoka, R., Rankin, S., Lin, S. C., Jonatan, D., Zorn, A. M. and Wells, J. M. (2007). Sox17 and Sox4 differentially regulate beta-catenin/T-cell factor activity and proliferation of colon carcinoma cells. Mol. Cell. Biol. 27, 7802-7815.
86. Stemmler, M. P. (2008). Cadherins in development and cancer. Mol. Biosyst. 4, 835-850.
87. Tepper, C. G., Gregg, J. P., Shi, X. B., Vinall, R. L., Baron, C. A., Ryan, P. E., Desprez, P. Y., Kung, H. J. and deVere White, R. W. (2005). Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate 65, 375-389.
88. Todorović, V., Desai, B. V., Patterson, M. J., Amargo, E. V., Dubash, A. D., Yin, T., Jones, J. C. and Green, K. J. (2010). Plakoglobin regulates cell motility through Rho- and fibronectin-dependent Src signaling. J. Cell Sci. 123, 3576-3586.
89. Valenta, T., Hausmann, G. and Basler, K. (2012). The many faces and functions of bcatenin. EMBO J. 31, 2714-2736.
90. van Heusden, G. P. H. (2009). 14-3-3 Proteins: insights from genome-wide studies in yeast. Genomics 94, 287-293.
91. van Roy, F. and Berx, G. (2008). The cell-cell adhesion molecule E-cadherin. Cell. Mol. Life Sci. 65, 3756-3788.
92. Vaseva, A. V. and Moll, U. M. (2009). The mitochondrial p53 pathway. Biochim. Biophys. Acta 1787, 414-420.
93. Wang, X., Peng, Y., Ma, Y. and Jahroudi, N. (2004). Histone H1-like protein participates in endothelial cell-specific activation of the von Willebrand factor promoter. Blood 104, 1725-1732.
94. Weisz, L., Oren, M. and Rotter, V. (2007). Transcription regulation by mutant p53. Oncogene 26, 2202-2211.
95. Williamson, L., Raess, N. A., Caldelari, R., Zakher, A., de Bruin, A., Posthaus, H., Bolli, R., Hunziker, T., Suter, M. M. and Mü ller, E. J. (2006). Pemphigus vulgaris identifies plakoglobin as key suppressor of c-Myc in the skin. EMBO J. 25, 3298-3309.
96. Winn, R. A., Bremnes, R. M., Bemis, L., Franklin, W. A., Miller, Y. E., Cool, C. and Heasley, L. E. (2002). c-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 21, 7497-7506.
97. Wu, H., Pomeroy, S. L., Ferreira, M., Teider, N., Mariani, J., Nakayama, K. I., Hatakeyama, S., Tron, V. A., Saltibus, L. F., Spyracopoulos, L. et al. (2011). UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat. Med. 17, 347-355.
98. Yi, B., Tan, S. X., Tang, C. E., Huang, W. G., Cheng, A. L., Li, C., Zhang, P. F., Li, M. Y., Li, J. L., Yi, H. et al. (2009). Inactivation of 14-3-3 s by promoter methylation correlates with metastasis in nasopharyngeal carcinoma. J. Cell. Biochem. 106, 858-866.
99. Yilmaz, M. and Christofori, G. (2010). Mechanisms of motility in metastasizing cells. Mol. Cancer Res. 8, 629-642.
100. Yin, T., Getsios, S., Caldelari, R., Kowalczyk, A. P., Mü ller, E. J., Jones, J. C. and Green, K. J. (2005). Plakoglobin suppresses keratinocyte motility through both cellcell adhesion-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA 102, 5420-5425.
101. Zhurinsky, J., Shtutman, M. and Ben-Ze'ev, A. (2000a). Differential mechanisms of LEF/TCF family-dependent transcriptional activation by b-catenin and plakoglobin. Mol. Cell. Biol. 20, 4238-4252.
102. Zhurinsky, J., Shtutman, M. and Ben-Ze'ev, A. (2000b). Plakoglobin and b-catenin: protein interactions, regulation and biological roles. J. Cell Sci. 113, 3127-3139.